New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:10 EDTCRISCuris closes $30M secured debt financing transaction
Curis announced that it has closed the previously announced $30M debt transaction with BioPharma-II, an investment fund managed by Pharmakon Advisors. The debt is secured with certain future royalties of Erivedge. "The completion of this transaction has significantly strengthened our capital position and we currently expect that we will end 2012 with approximately $56M-$58M in cash, cash equivalents and investments. We believe that this provides us with adequate capital to fund our currently planned operations into 2015. Importantly, our cash forecast does not include either potential milestones from our partners Genentech and Debiopharm or royalty revenues that we may receive in excess of quarterly payment caps under our debt arrangement, either of which could meaningfully increase our capital position if achieved," the company said.
News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:22 EDTCRISBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
16:14 EDTCRISCuris reports CUDC-907, CUDC-427 data
Subscribe for More Information
16:11 EDTCRISCuris, Debiopharm Group report preclinical data for Debio 0932
Curis and Debiopharm Group announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research, or AACR, that demonstrated synergy between Debio 0932 and various standard of care, or SOC, agents in multiple in vitro and xenograft models of non-small cell lung cancer, or NSCLC, and renal cell carcinoma, or RCC. Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced RCC patients. In a high throughput combination screen performed with six different human NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule and mTOR/ Akt targeting agents across all six cell lines. Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human xenograft models of NSCLC and RCC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use